<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>埃森哲（ACN）表示，通過埃森哲風險投資公司已投資於 Iridius，這是一家企業級人工智能基礎設施公司，專為高度監管的行業（包括生命科學和製藥領域）設計合規的人工智能解決方案。埃森哲和 Iridius 還將建立戰略合作伙伴關係，以支持生命科學組織在人工智能應用方面的擴展。投資條款未披露。</p>
<p>埃森哲和 Iridius 將構建覆蓋生命科學價值鏈的端到端合規工作流程，從監管提交和藥物警戒到臨牀和製造操作。</p>
<p>截至最後收盤，埃森哲的股價為 178.28 美元，下跌 6.22%。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

埃森哲

銥星通訊

<p>埃森哲（ACN）通過埃森哲風險投資公司投資了銥星通訊，這是一家企業級人工智能基礎設施公司。此次投資旨在增強生命科學和製藥等受監管行業的人工智能解決方案。此外，埃森哲和銥星通訊將建立戰略合作伙伴關係，以促進生命科學組織中的人工智能應用，重點關注整個價值鏈的合規工作流程。投資條款未披露，埃森哲的股票交易價格為 178.28 美元，下跌 6.22%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Accenture (ACN) said it has invested, through Accenture Ventures, in Iridius, an enterprise AI infrastructure company that designs compliant-by-design AI solutions for highly regulated industries, including life sciences and pharmaceuticals sectors. Accenture and Iridius will also form a strategic partnership to support life sciences organizations in scaling AI adoption. Terms of the investment were not disclosed.</p>
<div class="lb-trans"><p>埃森哲（ACN）表示，通過埃森哲風險投資公司已投資於 Iridius，這是一家企業級人工智能基礎設施公司，專為高度監管的行業（包括生命科學和製藥領域）設計合規的人工智能解決方案。埃森哲和 Iridius 還將建立戰略合作伙伴關係，以支持生命科學組織在人工智能應用方面的擴展。投資條款未披露。</p>
</div><p>Accenture and Iridius will build end-to-end compliance workflows across the life sciences value chain, from regulatory submissions and pharmacovigilance to clinical and manufacturing operations.</p>
<div class="lb-trans"><p>埃森哲和 Iridius 將構建覆蓋生命科學價值鏈的端到端合規工作流程，從監管提交和藥物警戒到臨牀和製造操作。</p>
</div><p>At last close, Accenture shares were trading at $178.28, down 6.22%.</p>
<div class="lb-trans"><p>截至最後收盤，埃森哲的股價為 178.28 美元，下跌 6.22%。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

埃森哲宣佈投資 Iridius